Figure 3. Progression-Free Survival of Patients With Programmed Death Ligand 1 (PD-L1)–Positive vs PD-L1–Negative Tumors.
The diamond indicates the pooled estimate, derived from the generic inverse variance (IV) and a fixed-effects model. HR indicates hazard ratio; Ipi, ipilimumab; and Nivo, nivolumab.